Apotex Inc. Acquires Topgen E.S.V. in Belgium from Zambon
Apotex Inc. announced the purchase from Zambon of the pharmaceutical company, Topgen, E.S.V. of Belgium. No acquisition price was disclosed. According to the company, Topgen, headquartered in Brussels, is the 7th largest generic pharmaceutical company in this country with approximately 30 generic registrations and has a nation-wide sales force that reaches over 4,000 doctors and 3,000 pharmacies.
"This acquisition represents an important milestone for Apotex International as it extends the organization's footprint in Europe and will be a launching pad for many E.U. products currently in the Apotex development pipeline," stated Andrew Kay, Apotex International President.
"The sale of Topgen furthers Zambon's strategy of focusing its Belgian operations on developing its portfolio of branded products, while simultaneously strengthening our relationship with Apotex, which is already a partner of Zambon and Chiesi in Italy through Doc Generici S.r.l.," explained Roberto Consonni, CEO of Zambon's Pharma Business.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Experts at Virgen del Rocío Hospital are studying the effectiveness of olive oil as a preeclampsia treatment

New findings on the effect of Epsom salt - Epsom salt receptor identified

University of Leicester researchers discover new fluorescent silicon nanoparticles - Research may ultimately track the uptake of drugs by the body's cells
Algeta begins first US clinical trial of Alpharadin in men with advanced prostate cancer

The first kobuviruses described from Africa
SciGene Signs Reagent Supply Agreement with Life Technologies
DNA "tricked" to act as nano-building blocks - McGill researchers find new ways to manufacture nanotubes of controlled geometry, stiffness and porosities
New method helps researchers decode genomes
Denosumab Demonstrated Superiority Over Zometa in Delay of Complications Due to Bone Metastases in Advanced Prostate Cancer
Merck, Employee Representatives Agree on Efficiency Plan for Germany - Company will reduce headcount in Germany by 1,100 positions - socially acceptable implementation has already started
Boom in smart pills will reach a new peak by 2018-2020
